EGFR and neoplasm: This approach enables CAR-T cells to effectively distinguish between tumor cells and unactivated EGFR present in normal tissues, thereby reducing toxicity to normal tissues and enhancing therapeutic specificity for EGFR-positive solid tumors [93].